(NP (NP Influence/NN) (PP of/IN (NP-COOD (NP estradiol/NN) and/CC (NP tamoxifen/NN))) (PP on/IN (NP (NP susceptibility/NN) (PP of/IN (NP human/JJ breast/NN cancer/NN cell/NN lines/NNS)) (PP to/TO (NP (NP lysis/NN) (PP by/IN (NP lymphokine-activated/JJ killer/NN cells/NNS)))))) ./.)
(S (NP-SBJ-58 (NP The/DT design/NN) (PP of/IN (NP (NP combination/NN (ADJP-COOD (ADJP hormonal/JJ) and/CC (ADJP immunotherapeutic/JJ)) protocols/NNS) (PP for/IN (NP breast/NN cancer/NN patients/NNS))))) (VP may/MD (VP be/VB (VP facilitated/VBN (NP *-58/-NONE-) (PP by/IN (NP-LGS (NP analysis/NN) (PP of/IN (NP preclinical/JJ (ADJP in/FW vitro/FW) model/JJ systems/NNS))))))) ./.)
(S (NP-SBJ-200 Estrogen/NN receptor/NN (ADJP-COOD (ADJP (ADJP positive/JJ) (PRN -LRB-/-LRB- (FRAG (ADJP ER+/JJ) :/: (NP MCF-7/NN)) -RRB-/-RRB-)) and/CC (ADJP (ADJP negative/JJ) (PRN -LRB-/-LRB- (FRAG (ADJP ER-/JJ) :/: (NP MDA-MB-231/NN)) -RRB-/-RRB-))) human/JJ breast/NN cancer/NN cell/NN lines/NNS) (VP were/VBD (VP utilized/VBN (NP *-200/-NONE-) (S (NP-SBJ */-NONE-) (VP to/TO (VP evaluate/VB (NP (NP the/DT effects/NNS) (PP of/IN (NP-COOD (NP (NP tamoxifen/NN) (PRN -LRB-/-LRB- (NP TAM/NN) -RRB-/-RRB-)) and/CC (NP (NP estradiol/NN) (PRN -LRB-/-LRB- (NP E2/NN) -RRB-/-RRB-)))) (PP on/IN (NP (NP modulation/NN) (PP of/IN (NP (NP breast/NN cancer/NN target/NN susceptibility/NN) (PP to/TO (NP (NP lysis/NN) (PP by/IN (NP (NP (NP lymphokine-activated/JJ killer/NN) (PRN -LRB-/-LRB- (NP LAK/NN) -RRB-/-RRB-)) cells/NNS)))))))))))))) ./.)
(S (NP-SBJ E2-stimulated/JJ ER+/JJ cells/NNS) (VP were/VBD (ADJP-PRD (ADJP more/RBR susceptible/JJ (PP to/TO (NP (NP lysis/NN) (PP by/IN (NP LAK/NN cells/NNS))))) (PP than/IN (NP corresponding/VBG (UCP-COOD (ADJP TAM-treated/JJ) or/CC (NP control/NN)) cells/NNS))) ,/, (SBAR while/IN (S (NP-SBJ (NP treatment/NN) (PP of/IN (NP ER-/JJ cells/NNS)) (PP with/IN (NP (NP-COOD either/CC (NP E2/NN) or/CC (NP TAM/NN)) (ADVP alone/RB)))) (VP did/VBD not/RB (VP alter/VB (PP from/IN (NP control/NN)) (NP (NP their/PRP$ susceptibility/NN) (PP to/TO (NP this/DT immune-mediated/JJ lysis/NN)))))))) ./.)
(S (NP-SBJ (NP All/DT (ADJP-COOD (ADJP ER+/JJ) and/CC (ADJP ER-/JJ)) cells/NNS) (VP tested/VBN (NP */-NONE-))) (VP remained/VBD (ADJP-PRD sensitive/JJ (PP *ICH*-201/-NONE-)) (PP-TMP after/IN (NP (NP treatment/NN) (PP with/IN (NP TAM/NN)))) (PP-201 to/TO (NP (NP lysis/NN) (PP by/IN (NP LAK/NN cells/NNS))))) ./.)
(S (PP In/IN (NP addition/NN)) ,/, (NP-SBJ-59 (NP an/DT (ADJP (NP adenocarcinoma/NN) reactive/JJ) (ADJP human-mouse/JJ chimeric/JJ) monoclonal/JJ antibody/NN) (PRN -LRB-/-LRB- (NP ING-1/NN) -RRB-/-RRB-)) (VP was/VBD (ADJP-PRD able/JJ (S (NP-SBJ *-59/-NONE-) (VP to/TO (ADVP significantly/RB) (VP boost/VB (NP (NP (ADJP (ADVP in/FW vivo/FW) generated/VBN) (ADJP LAK/NN cell-mediated/JJ) lysis/NN) (PP of/IN (NP (UCP-COOD (NP control/NN) ,/, (ADJP E2-treated/JJ) ,/, and/CC (ADJP TAM-treated/JJ)) (ADJP-COOD (ADJP ER+/JJ) and/CC (ADJP ER-/JJ)) cells/NNS)))))))) ./.)
(S (NP-SBJ These/DT (ADJP in/FW vitro/FW) results/NNS) (VP provide/VBP (NP (NP a/DT preclinical/JJ rationale/NN) (PP for/IN (NP (NP (ADJP in/FW vivo/FW) testing/NN) (PP of/IN (NP (NP-COOD (NP TAM/NN) ,/, (NP (NP interleukin-2/NN) (PRN -LRB-/-LRB- (NP IL-2/NN) -RRB-/-RRB-)) ,/, and/CC (NP breast/NN cancer/NN reactive/JJ antibody-dependent/JJ cellular/JJ cytotoxicity/NN)) (VP facilitating/VBG (NP antibody/NN) (PP in/IN (NP (NP patients/NNS) (PP with/IN (NP (UCP-COOD (ADJP refractory/JJ) or/CC (NP high/JJ risk/NN)) breast/NN cancer/NN))))))))))) ./.)
